Skip to main content
main-content

Breast cancer

19-05-2017 | Oncology | News | Article

In other news

Here we report on osteoporosis therapy in breast cancer patients, the feasibility of an alternative formulation of rituximab in follicular lymphoma, the effects of extended use of anamorelin on lung cancer-related cachexia, and the 3-year results of the COMBI-d trial.

19-05-2017 | Breast cancer | News | Article

Adjuvant gemcitabine not recommended in early breast cancer

Gemcitabine offers no survival benefit, but increases toxicity, when added to anthracycline and taxane-containing adjuvant chemotherapy in early breast cancer, results from the tAnGo trial show.

Source:

Lancet Oncol 2017; Advance online publication

02-05-2017 | Breast cancer | News | Article

Low mitochondrial DNA points to breast cancer anthracycline efficacy

Among women with breast cancer treated with anthracyclines in the adjuvant or advanced setting, outcomes are better for those with low versus high levels of mitochondrial DNA in their primary tumors, suggests an analysis of biobank specimens.

Source:

Clin Cancer Res 2017; Advance online publication

07-04-2017 | Breast cancer | News | Article

Radiotherapy boost reduces DCIS recurrence risk

A radiotherapy boost to the tumor bed following whole-breast radiotherapy for ductal carcinoma in situ significantly reduces the risk for ipsilateral breast tumor recurrence, pooled study data show.

Source:

JAMA Oncol 2017; Advance online publication

31-03-2017 | Breast cancer | News | Article

Commercial mouthwash substantially reduces everolimus-related stomatitis

An inexpensive, commercially available dexamethasone mouthwash substantially reduces the incidence and severity of stomatitis in patients receiving everolimus and exemestane for breast cancer, US study data show.

Source:

Lancet Oncol 2017; Advance online publication

27-03-2017 | Breast cancer | News | Article

Brain metastases in newly diagnosed breast cancer patients profiled

Patients with hormone receptor-negative/human epidermal growth factor receptor 2-positive breast cancer have the highest incidence of brain metastases at diagnosis, followed by those with triple-negative disease, population-based study data show.

Source:

JAMA Oncol 2017; Advance online publication

image credits